Simplex Trading, LLC Kymera Therapeutics, Inc. Transaction History

Simplex Trading, LLC

$3.28 Billion
Q4 2024

A detailed history of Simplex Trading, LLC transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 20 shares of KYMR stock, worth $736. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$736

% of portfolio

0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$39.06 - $51.84 $781 - $1,036	20 New	20 $0
Q3 2022 Nov 04, 2022	BUY	$20.91 - $34.27 $76,237 - $124,948	3,646 Added 1321.01%	3,922 $85,000
Q2 2022 Aug 03, 2022	SELL	$14.13 - $42.55 $48,734 - $146,754	-3,449 Reduced 92.59%	276 $5,000
Q1 2022 May 02, 2022	BUY	$35.3 - $64.68 $131,316 - $240,609	3,720 Added 74400.0%	3,725 $157,000
Q4 2021 Feb 23, 2022	SELL	$49.91 - $65.56 $67,628 - $88,833	-1,355 Reduced 99.63%	5 $0
Q3 2021 Oct 28, 2021	BUY	$47.8 - $66.66 $48,660 - $67,859	1,018 Added 297.66%	1,360 $76,000
Q2 2021 Aug 12, 2021	BUY	$31.08 - $51.95 $10,629 - $17,766	342 New	342 $16,000

Others Institutions Holding KYMR

# of Institutions

186

Shares Held

65.5M

Call Options Held

49.6K

Put Options Held

17K

Price T Rowe Associates Inc Baltimore, MD

6.87M
Shares

$253 Million
0.03% of portfolio
Baker Bros. Advisors LP New York, NY

6M
Shares

$221 Million
2.67% of portfolio
Wellington Management Group LLP Boston, MA

5.31M
Shares

$195 Million
0.04% of portfolio
Bvf Inc San Francisco, CA

5.16M
Shares

$190 Million
7.77% of portfolio
Avoro Capital Advisors LLC New York, NY

5.15M
Shares

$190 Million
3.02% of portfolio

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.01B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Account